title: Novel approaches to the treatment of small-cell lung cancer.
abstract: Small-cell lung cancer (SCLC) is characterized by its initial responsiveness to chemotherapy and the appearance of early metastases. Although combination chemotherapy, in some instances together with radiation, has improved the prognosis of this disease, in most patients SCLC ultimately recurs in a drug-resistant form. Several new strategies for the eradication of SCLC are being explored at the preclinical level. The identification of selective target molecules on the surface of SCLC cells, together with the progress made in antibody engineering, have provided new generations of antibodies and immunoconjugates as well as growth factor antagonists and inhibitors. In addition, recent advances in understanding the biology of SCLC have stimulated new investigations searching to counter the molecular basis underlying the increased proliferation and the apoptosis deficiency of SCLC cells. This can be achieved using antisense oligodeoxynucleotides that repress the expression of growth factor receptors and anti-apoptosis genes, or by gene replacement to compensate for the loss or inactivation of tumor suppressor genes.
authors.affiliation: Department of Internal Medicine, University Hospital Zürich, Switzerland. uwe.zangemeister@dim.usz.ch
authors.forename: U
authors.initials: U
authors.lastname: Zangemeister-Wittke
authors.forename: R A
authors.initials: RA
authors.lastname: Stahel
mesh_terms: D000912:Antibodies, Neoplasm / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000235:genetics; D018288:Carcinoma, Small Cell / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D019008:Drug Resistance, Neoplasm; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D018796:Immunoconjugates; D016376:Oligonucleotides, Antisense